Description
A proposal has been submitted to update the WHO Model List of Essential Medicines (EML) with an additional tablet formulation of an existing antibiotic. The application seeks to include a new 875 mg + 125 mg tablet formulation of amoxicillin + clavulanic acid in the EML for treating mild community-acquired pneumonia and intra-abdominal infections in adults. These are established indications for the drug, which is already listed in the EML in other strengths and formulations. This is not a request to add a new medicine but to expand available formulations, aiming to enhance clinical flexibility and treatment access.